Antiretroviral treatment failure and associated factors among HIV patients on first-line antiretroviral treatment in Sekota, northeast Ethiopia

Table 2 The distribution of virological failure per clinical factors at Tefera Hailu Memorial Hospital, Sekota, northeast Ethiopia, 2019

Variables	Category	N = 295	% from N	VTF = 49	%
Current ART regimen	1c	53	18.0	16	32.65
	1d	82	27.8	12	24.49
	1e	135	45.8	15	30.61
	1f	16	5.4	2	4.08
	4c	9	3.1	4	8.16
Baseline ART regimen	1a	26	8.8	4	8.16
	1b	40	13.6	8	16.33
	1c	37	12.5	8	16.33
	1d	68	23.1	12	24.49
	1e	110	37.3	11	22.45
	4c	14	4.7	6	12.24
Drug substitution	None	208	70.5	31	63.27
Drug substitution	Once	87	29.5	18	36.73
Current CD4 result	≤ 100	23	7.8	14	28.57
	101–250	86	29.2	20	40.82
	251–500	88	29.8	11	22.45
	501 +	98	33.2	4	8.16
Current clinical stage	I	265	89.8	34	69.39
	II	24	8.13	12	24.49
	III	6	2.03	3	6.12
Baseline clinical stage	I	59	20.0	7	14.29
	II	124	42.0	21	42.86
	III	98	33.2	18	36.73
	IV	14	4.7	3	6.12
The dose of ART per day	Once	131	44.4	15	30.61
The dose of ART per day	Twice	164	55.6	34	69.39
Drug interruption	No	261	88.5	37	75.51
Drug interruption	Yes	34	11.5	12	24.49
Drug adherence	≥ 95%	189	64.1	11	22.45
Drug adherence	< 95%	106	35.9	38	77.55
Prophylaxis use	No	285	96.6	44	89.80
Prophylaxis use	Yes	10	3.4	5	10.80
Baseline function status	Bedridden	28	9.5	7	14.29
	Ambulatory	184	62.4	28	57.14
	Working	83	28.1	14	28.57
TB history	No	242	82	36	73.47
TB history	Yes	53	18	13	26.53
Disclosure	No	71	24.1	10	20.41
Disclosure	Yes	224	75.9	39	79.59
Duration/month on ART	6–24	29	9.8	1	2.04
	25–48	39	13.2	4	8.16
	49–72	57	19.3	7	14.29
	73 +	170	57.6	37	75.51
Baseline CD4 result	≤ 100	150	50.8	26	53.06
	101–250	88	29.8	15	30.61
	251–500	28	9.5	3	6.12
	501 +	29	9.8	5	10.20

^{1a = d4T/3TC/NVP, 1b = d4T/3TC/NVP, 1c = AZT/3TC/NVP, 1d = AZT/3TC/EFV, 1f = TDF/3TC/NVP, 4c = AZT/3TC/NVP, VTF virological treatment failure, N total participants, TB tuberculosis}

ISSN: 1742-6405